Central Pacific Bank Trust Division Invests $935,000 in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Central Pacific Bank Trust Division acquired a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 42,427 shares of the company’s stock, valued at approximately $935,000.

Several other hedge funds and other institutional investors have also made changes to their positions in TEVA. UMB Bank n.a. lifted its position in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after acquiring an additional 2,067 shares during the last quarter. Smithfield Trust Co increased its position in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $50,000. Claro Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $52,000. Finally, Venturi Wealth Management LLC purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $60,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $20.88.

Teva Pharmaceutical Industries Stock Down 0.3 %

Shares of NYSE:TEVA opened at $21.24 on Friday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.75 and a fifty-two week high of $22.80. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The firm’s 50-day simple moving average is $18.60 and its 200-day simple moving average is $17.87. The company has a market cap of $24.06 billion, a price-to-earnings ratio of -24.99, a PEG ratio of 0.99 and a beta of 0.79.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.